内部人士可能会获得普通股东无法享受的可观财务利益。
拟议的交易可能包含限制更优竞争报价的条款。
鼓励股东与本公司联系，讨论他们的权利和选择，且无需支付任何费用或承担任何义务。我们将以风险代理的方式处理任何事务，您无需承担我们的法律费用或开支。
, /PRNewswire/ -- Halper Sadeh LLC，一家投资者权益法律事务所，正在调查以下公司是否存在违反联邦证券法和/或对股东的信托责任的行为，涉及：
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) 以每股 41.00 美元现金及一项不可转让的或有价值权出售给 Biogen Inc.，该权利允许在满足某些年度全球净销售阈值的情况下，获得两笔每股 2.00 美元的付款。如果您是 Apellis 的股东， 请点击这里了解您的法律权利和选择。
Centessa Pharmaceuticals plc (NASDAQ: CNTA) 以每股 38.00 美元现金及一项不可转让的或有价值权出售给 Eli Lilly and Company，该权利允许持有人在达到某些里程碑的情况下，最多获得 9.00 美元的总额。如果您是 Centessa 的股东， 请点击这里了解您的法律权利和选择。
Kezar Life Sciences, Inc. (NASDAQ: KZR) 以每股 6.955 美元现金及一项不可转让的或有价值权出售给 Aurinia Pharmaceuticals Inc.。如果您是 Kezar 的股东， 请点击这里了解您的法律权利和选择。
代表股东，Halper Sadeh LLC 可能寻求增加对价、额外披露和信息，或其他救济和利益。
Halper Sadeh LLC 代表全球的投资者，帮助他们应对证券欺诈和企业不当行为。我们的律师在实施公司改革和为受欺诈投资者追回数百万美元方面发挥了重要作用。
律师广告。以往的结果并不保证类似的结果。
联系信息：
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
世界贸易中心一号
85 层
纽约，NY 10007
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com
来源 Halper Sadeh LLP
<img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDEwJk5ld3NJdGVtSWQ9TlkzMTY2MCZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MTAxMzM0UFJfTkVXU19VU1BSX19fX19OWTMxNjYw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDEwJk5ld3NJdGVtSWQ9TlkzMTY2MCZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MTAxMzM0UFJfTkVXU19VU1BSX19fX19OWTMxNjYw"/>

纽交所高增长板生物技术指数 ETF - First Trust

美国制药 ETF - iShares

医疗业 ETF - Vanguard

Halper Sadeh LLC 正在调查 Apellis Pharmaceuticals (APLS)、Centessa Pharmaceuticals (CNTA) 和 Kezar Life Sciences (KZR) 是否存在违反联邦证券法和违反信托责任的潜在行为。该公司担心内部人士可能会在普通股东的利益受损的情况下获得财务利益，原因是拟议交易条款。鼓励股东与该公司联系，讨论他们的权利和选择，且无需支付费用。调查重点是这些公司向更大公司的销售，可能会寻求增加对股东的考虑或披露

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
<div class="lb-trans">内部人士可能会获得普通股东无法享受的可观财务利益。
</div>The proposed transactions may contain terms that could limit superior competing offers.
<div class="lb-trans">拟议的交易可能包含限制更优竞争报价的条款。
</div>Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
<div class="lb-trans">鼓励股东与本公司联系，讨论他们的权利和选择，且无需支付任何费用或承担任何义务。我们将以风险代理的方式处理任何事务，您无需承担我们的法律费用或开支。
</div>, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
<div class="lb-trans">, /PRNewswire/ -- Halper Sadeh LLC，一家投资者权益法律事务所，正在调查以下公司是否存在违反联邦证券法和/或对股东的信托责任的行为，涉及：
</div>Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)'s sale to Biogen Inc. for $41.00 per share in cash and a nontransferable contingent value right for the right to receive two payments of $2.00 per share each, contingent on certain annual global net sales thresholds being met for SYFOVRE. If you are an Apellis shareholder, click here to learn more about your legal rights and options.
<div class="lb-trans">Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) 以每股 41.00 美元现金及一项不可转让的或有价值权出售给 Biogen Inc.，该权利允许在满足某些年度全球净销售阈值的情况下，获得两笔每股 2.00 美元的付款。如果您是 Apellis 的股东， 请点击这里了解您的法律权利和选择。
</div>Centessa Pharmaceuticals plc (NASDAQ: CNTA)'s sale to Eli Lilly and Company for $38.00 in cash per share plus one non-transferrable contingent value right entitling the holder to receive up to an aggregate of $9.00 subject to the achievement of certain milestones. If you are a Centessa shareholder, click here to learn more about your legal rights and options.
<div class="lb-trans">Centessa Pharmaceuticals plc (NASDAQ: CNTA) 以每股 38.00 美元现金及一项不可转让的或有价值权出售给 Eli Lilly and Company，该权利允许持有人在达到某些里程碑的情况下，最多获得 9.00 美元的总额。如果您是 Centessa 的股东， 请点击这里了解您的法律权利和选择。
</div>Kezar Life Sciences, Inc. (NASDAQ: KZR)'s sale to Aurinia Pharmaceuticals Inc. for $6.955 in cash per share and one non-transferable contingent value right. If you are a Kezar shareholder, click here to learn more about your legal rights and options.
<div class="lb-trans">Kezar Life Sciences, Inc. (NASDAQ: KZR) 以每股 6.955 美元现金及一项不可转让的或有价值权出售给 Aurinia Pharmaceuticals Inc.。如果您是 Kezar 的股东， 请点击这里了解您的法律权利和选择。
</div>On behalf of shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures and information, or other relief and benefits.
<div class="lb-trans">代表股东，Halper Sadeh LLC 可能寻求增加对价、额外披露和信息，或其他救济和利益。
</div>Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
<div class="lb-trans">Halper Sadeh LLC 代表全球的投资者，帮助他们应对证券欺诈和企业不当行为。我们的律师在实施公司改革和为受欺诈投资者追回数百万美元方面发挥了重要作用。
</div>Attorney Advertising. Prior results do not guarantee a similar outcome.
<div class="lb-trans">律师广告。以往的结果并不保证类似的结果。
</div>Contact Information:
<div class="lb-trans">联系信息：
</div>Halper Sadeh LLC
<div class="lb-trans">Halper Sadeh LLC
</div>Daniel Sadeh, Esq.
<div class="lb-trans">Daniel Sadeh, Esq.
</div>Zachary Halper, Esq.
<div class="lb-trans">Zachary Halper, Esq.
</div>One World Trade Center
<div class="lb-trans">世界贸易中心一号
</div>85th Floor
<div class="lb-trans">85 层
</div>New York, NY 10007
<div class="lb-trans">纽约，NY 10007
</div>(212) 763-0060
<div class="lb-trans">(212) 763-0060
</div>[email protected]
<div class="lb-trans">[email protected]
</div>[email protected]
<div class="lb-trans">[email protected]
</div>https://www.halpersadeh.com
<div class="lb-trans">https://www.halpersadeh.com
</div>SOURCE Halper Sadeh LLP
<div class="lb-trans">来源 Halper Sadeh LLP
</div><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDEwJk5ld3NJdGVtSWQ9TlkzMTY2MCZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MTAxMzM0UFJfTkVXU19VU1BSX19fX19OWTMxNjYw" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=NY31660&amp;Transmission_Id=202604101334PR_NEWS_USPR_____NY31660&amp;DateId=20260410"/>

13:34 ETAre APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders?

prnewswire

医疗业 ETF - SPDR

Kezar Life Sciences

Centessa Pharmaceuticals

2 倍做多纳斯达克生物技术 ETF - ProShares

Invesco Nasdaq Biotechnology ETF

纳斯达克生物科技指数 ETF - iShares Nasdaq

Apellis Pharma

标普生物技术 3 倍做多 - Direxion

标普生物技术 ETF - SPDR

动态生物技术与基因组 ETF - Invesco

标普全球医疗股指数 ETF - iShares

生物科技 ETF - VanEck Vectors

医药突破 ETF - ALPS

基因改革 ETF - ARK

Apellis Pharma、Centessa Pharmaceuticals、Kezar Life Sciences 是否为其股东争取到了公平的交易？